Austar Lifesciences Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Austar Lifesciences.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	25.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Austar Lifesciences no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:6118 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	1,764	-33	N/A	N/A	N/A
6/30/2023	2,089	2	-136	-60	N/A
3/31/2023	2,159	45	-155	-49	N/A
12/31/2022	2,229	87	-175	-38	N/A
9/30/2022	2,246	96	-233	-81	N/A
6/30/2022	2,264	105	-291	-125	N/A
3/31/2022	2,139	191	-255	-114	N/A
12/31/2021	2,015	277	-219	-103	N/A
9/30/2021	1,824	258	-128	-32	N/A
6/30/2021	1,633	238	-36	40	N/A
3/31/2021	1,465	136	-26	46	N/A
12/31/2020	1,296	33	-15	52	N/A
9/30/2020	1,193	25	-11	48	N/A
6/30/2020	1,089	17	-7	43	N/A
3/31/2020	1,069	12	8	41	N/A
12/31/2019	1,049	8	23	38	N/A
9/30/2019	1,007	8	-33	-4	N/A
6/30/2019	966	8	-89	-46	N/A
3/31/2019	891	4	-104	-62	N/A
12/31/2018	817	0	-119	-78	N/A
9/30/2018	724	-16	-63	-37	N/A
6/30/2018	631	-33	-7	4	N/A
3/31/2018	589	-43	-11	-1	N/A
12/31/2017	547	-54	-16	-6	N/A
9/30/2017	587	-43	N/A	-20	N/A
6/30/2017	628	-32	N/A	-33	N/A
3/31/2017	650	-25	N/A	-32	N/A
12/31/2016	673	-19	N/A	-30	N/A
9/30/2016	648	-17	N/A	3	N/A
6/30/2016	624	-16	N/A	37	N/A
3/31/2016	626	-5	N/A	49	N/A
12/31/2015	628	6	N/A	62	N/A
9/30/2015	640	24	N/A	26	N/A
6/30/2015	652	43	N/A	-9	N/A
3/31/2015	666	54	N/A	-37	N/A
12/31/2014	680	65	N/A	-64	N/A
9/30/2014	676	58	N/A	-51	N/A
6/30/2014	672	51	N/A	-37	N/A
3/31/2014	689	52	N/A	17	N/A
12/31/2013	705	54	N/A	71	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 6118 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 6118 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 6118 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 6118 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 6118 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 6118 se prevé que sea elevada dentro de 3 años.

Austar Lifesciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Recent updates

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: CN¥0.063 loss per share (vs CN¥0.17 profit in FY 2022)

Austar Lifesciences Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

New major risk - Share price stability

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

First half 2023 earnings released: CN¥0.078 loss per share (vs CN¥0.089 profit in 1H 2022)

Investor sentiment deteriorates as stock falls 30%

Austar Lifesciences Limited to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.54 in FY 2021)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 25%

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

First half 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.42 in 1H 2021)

Investor sentiment deteriorated over the past week

Austar Lifesciences Limited to Report First Half, 2022 Results on Aug 29, 2022

Austar Lifesciences Limited (SEHK:6118) acquired an unknown minority interest in Noozle Fluid Technology (Shanghai) Co., Ltd..

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Less than half of directors are independent

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Investor sentiment improved over the past week

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorated over the past week

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

First half 2021 earnings released: EPS CN¥0.42 (vs CN¥0.025 in 1H 2020)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Full year 2020 earnings released: EPS CN¥0.065 (vs CN¥0.016 in FY 2019)

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.016 in FY 2019)

Austar Lifesciences Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

An affiliate of Pall Corporation entered into an agreement to acquire 60% in PALL-AUSTAR Lifesciences Limited from Austar Lifesciences Limited (SEHK:6118) for approximately CNY 220 million.

New 90-day high: HK$6.15

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

New 90-day high: HK$4.02

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

First half earnings released

New 90-day low - HK$3.18

First half earnings released

Austar Lifesciences Limited to Report First Half, 2020 Results on Aug 27, 2020

New 90-day low - HK$3.23

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento